Compounders Research Compare

Entera Bio Ltd.(ENTX)

Biotechnology · Jerusalem, JM

$2.60-0.02 (-0.95%)

Delayed quote: Oct 6, 2026, 11:25 AM EDT

About Entera Bio Ltd.

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.

Jerusalem, JM

21 employees

www.enterabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Miranda J. Toledano

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T15:26:47.210Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:26:47.210Z.

Quote observation: 2026-10-06T15:25:23.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 127,908,069
Total debt · period ending 2026-06-30: 425,000
Cash · period ending 2026-06-30: 11,309,000
TTM free cash flow · period ending 2026-06-30: -11,400,438

FMP input reference: 5ff4a69d5e0bd829addfa263bba904bf87580f902e4d2830b11cef9910c58a28

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ENTX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

ENTX Competitors' EV/FCF Ratio

Entera Bio Ltd.

Current

Market Cap

$127.91M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Health Catalyst, Inc.

Market Cap

$130.05M

EV/FCF Ratio

18.33x

TTM Avg

24.01x

3Y Avg

24.01x

5Y Avg

24.01x

NRx Pharmaceuticals, Inc.

Market Cap

$125.34M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cibus, Inc.

Market Cap

$122.13M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Organigram Global Inc.

Market Cap

$132.48M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

enGene Holdings Inc.

Market Cap

$122.59M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TuHURA Biosciences, Inc.

Market Cap

$121.00M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LifeMD, Inc.

Market Cap

$135.41M

EV/FCF Ratio

N/A

TTM Avg

61.40x

3Y Avg

555.49x

5Y Avg

549.31x

Freenome, Inc.

Market Cap

$134.92M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KORU Medical Systems, Inc.

Market Cap

$136.88M

EV/FCF Ratio

500.37x

TTM Avg

1051.55x

3Y Avg

1051.55x

5Y Avg

1051.55x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Entera Bio Ltd. (ENTX)	$127.91M	N/A	N/A	N/A	N/A
Health Catalyst, Inc. (HCAT)vs ›	$130.05M	18.33x	24.01x	24.01x	24.01x
NRx Pharmaceuticals, Inc. (NRXP)vs ›	$125.34M	N/A	N/A	N/A	N/A
Cibus, Inc. (CBUS)vs ›	$122.13M	N/A	N/A	N/A	N/A
Organigram Global Inc. (OGI)vs ›	$132.48M	N/A	N/A	N/A	N/A
enGene Holdings Inc. (ENGN)vs ›	$122.59M	N/A	N/A	N/A	N/A
TuHURA Biosciences, Inc. (HURA)vs ›	$121.00M	N/A	N/A	N/A	N/A
LifeMD, Inc. (LFMD)vs ›	$135.41M	N/A	61.40x	555.49x	549.31x
Freenome, Inc. (FRNM)vs ›	$134.92M	N/A	N/A	N/A	N/A
KORU Medical Systems, Inc. (KRMD)vs ›	$136.88M	500.37x	1051.55x	1051.55x	1051.55x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics